Fate Therapeutics Earnings Reports

Fate Therapeutics reported total revenue of $1.6 million and a net loss of $41.3 million for the first quarter of 2025. The company ended the quarter with $272.7 million in cash, cash equivalents, and investments, providing a projected operating runway through the first half of 2027. Key business updates included positive developments for their FT819 program, including RMAT designation from the FDA and expansion of the Phase 1 study.

Fate Therapeutics reported a net loss of $52.153 million for Q4 2024, with total revenue of $1.860 million. The company ended the year with $306.7 million in cash, cash equivalents, and investments, projecting an operating runway through the end of 2026. Key clinical advancements include initiating Phase 1 dose expansion for FT819 in SLE with a flu-free conditioning regimen and treating the first FT819 patient without conditioning chemotherapy.

Fate Therapeutics reported $3.1 million in revenue for the third quarter of 2024, primarily from preclinical development activities under its collaboration with Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $330.5 million as of September 30, 2024, which is projected to provide an operating runway through the end of 2026.

Fate Therapeutics reported $6.8 million in revenue for the second quarter of 2024, derived from a milestone achievement and preclinical development activities under its collaboration with Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $352.0 million as of June 30, 2024, with a projected operating runway through YE26.

Fate Therapeutics reported its Q1 2024 financial results, including revenue of $1.9 million and cash, cash equivalents, and investments of $391.1 million. The company also made progress across three key areas of clinical focus with FT819, FT522 and FT825 programs.

Fate Therapeutics reported $1.7 million in revenue for Q4 2023, primarily from preclinical development activities under its collaboration with Ono. The company's cash, cash equivalents, and investments totaled $316.2 million as of December 31, 2023. Clinical development is ongoing across several iPSC-derived cellular immunotherapy programs.

Fate Therapeutics reported $1.9 million in revenue for the third quarter of 2023. The company's cash, cash equivalents, and investments totaled $349.7 million as of September 30, 2023, providing a cash runway into the second half of 2025. Several key milestones were achieved, including the initiation of patient enrollment in the Phase 1 study of FT522 and the FDA clearance of IND applications for FT825/ONO-8250 and FT819.

Fate Therapeutics reported $0.9 million in revenue for Q2 2023 and ended the quarter with $385.2 million in cash, cash equivalents, and investments. The company is advancing its FT522, FT819, and FT576 programs and plans to submit an IND application for FT825/ONO-8250 in the second half of 2023.

Fate Therapeutics reported a revenue of $59.0 million for Q1 2023, including $52.3 million from the termination of the Janssen collaboration and $6.7 million from the ONO collaboration. The company's cash, cash equivalents, and investments totaled $412.8 million, supporting operations into the second half of 2025. Strategic pipeline prioritization and corporate restructuring were completed during the quarter.

Fate Therapeutics reported revenue of $44.4 million for Q4 2022, derived from collaborations with Janssen and ONO. The company ended the year with approximately $475 million in cash, cash equivalents, and receivables. They are focusing on advancing innovative programs and reducing expenses to achieve key clinical milestones.

Fate Therapeutics reported $15.0 million in revenue for the third quarter of 2022, derived from collaborations with Janssen and ONO, and cash, cash equivalents and investments totaled $519.1 million as of September 30, 2022.

Fate Therapeutics reported a revenue of $18.5 million for the second quarter of 2022, derived from collaborations with Janssen and ONO. The company's cash, cash equivalents, and investments totaled $580.8 million as of June 30, 2022. Research and development expenses were $81.3 million, while general and administrative expenses were $20.4 million for the same period.

Fate Therapeutics reported $18.4 million in revenue for Q1 2022, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $641.7 million as of March 31, 2022.

Fate Therapeutics reported fourth quarter and full year 2021 financial results. The company's cash, cash equivalents and investments as of December 31, 2021 were $716.6 million. Revenue was $17.1 million for the fourth quarter of 2021.

Fate Therapeutics reported a revenue of $14.2 million for the third quarter of 2021, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $803.6 million as of September 30, 2021. The company is advancing its iPSC-derived NK cell product candidates.

Fate Therapeutics reported revenue of $13.4 million for the second quarter of 2021, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $845.1 million as of June 30, 2021.

Fate Therapeutics reported its Q1 2021 financial results, including revenue of $11.1 million. The company's cash, cash equivalents, and investments totaled $888.4 million and the company raised $460 million through a public offering.

Fate Therapeutics reported a revenue of $15.9 million for the fourth quarter of 2020, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $482.9 million as of December 31, 2020. Research and development expenses were $39.0 million, and general and administrative expenses were $10.3 million for the quarter.

Fate Therapeutics reported revenue of $7.6 million for the third quarter of 2020, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $502.0 million as of September 30, 2020.

Fate Therapeutics reported its Q2 2020 financial results, highlighting a revenue of $5.5 million and ending the quarter with $533.4 million in cash and short-term investments. The company also reported a partial response with FT596 monotherapy and initiated enrollment with FT596 in combination with Rituximab for B-cell Lymphoma.

Fate Therapeutics reported its Q1 2020 financial results, including revenue of $2.5 million and cash, cash equivalents, and investments of $219.4 million. They also highlighted the formation of a worldwide collaboration with Janssen and the treatment of the first patient with FT596.

Fate Therapeutics reported fourth-quarter results, highlighting clinical advancements in its iPSC-derived cancer immunotherapy programs, including FT500, FT516, and FT596, and ended the quarter with $261 million in cash, cash equivalents and marketable securities.